UNLABELLED: The vitronectin receptor integrin alphavbeta3 promotes angiogenesis by mediating migration and proliferation of endothelial cells, but also drives fibrogenic activation of hepatic stellate cells (HSCs) in vitro. Expecting antifibrotic synergism, we studied the effect of alphavbeta3 inhibition in two in vivo models of liver fibrogenesis. Liver fibrosis was induced in rats by way of bile duct ligation (BDL) for 6 weeks or thioacetamide (TAA) injections for 12 weeks. A specific alphavbeta3 (alphavbeta5) inhibitor (Cilengitide) was given intraperitoneally twice daily at 15 mg/kg during BDL or after TAA administration. Liver collagen was determined as hydroxyproline, and gene expression was quantified by way of quantitative polymerase chain reaction. Liver angiogenesis, macrophage infiltration, and hypoxia were assessed by way of CD31, CD68 and hypoxia-inducible factor-1alpha immunostaining. Cilengitide decreased overall vessel formation. This was significant in portal areas of BDL and septal areas of TAA fibrotic rats and was associated with a significant increase of liver collagen by 31% (BDL) and 27% (TAA), and up-regulation of profibrogenic genes and matrix metalloproteinase-13. Treatment increased gamma glutamyl transpeptidase in both models, while other serum markers remained unchanged. alphavbeta3 inhibition resulted in mild liver hypoxia, as evidenced by up-regulation of hypoxia-inducible genes. Liver infiltration by macrophages/Kupffer cells was not affected, although increases in tumor necrosis factor alpha, interleukin-18, and cyclooxygenase-2 messenger RNA indicated modest macrophage activation. CONCLUSION: Specific inhibition of integrin alphavbeta3 (alphavbeta5) in vivo decreased angiogenesis but worsened biliary (BDL) and septal (TAA) fibrosis, despite its antifibrogenic effect on HSCs in vitro. Angiogenesis inhibitors should be used with caution in patients with hepatic fibrosis.
UNLABELLED: The vitronectin receptor integrin alphavbeta3 promotes angiogenesis by mediating migration and proliferation of endothelial cells, but also drives fibrogenic activation of hepatic stellate cells (HSCs) in vitro. Expecting antifibrotic synergism, we studied the effect of alphavbeta3 inhibition in two in vivo models of liver fibrogenesis. Liver fibrosis was induced in rats by way of bile duct ligation (BDL) for 6 weeks or thioacetamide (TAA) injections for 12 weeks. A specific alphavbeta3 (alphavbeta5) inhibitor (Cilengitide) was given intraperitoneally twice daily at 15 mg/kg during BDL or after TAA administration. Liver collagen was determined as hydroxyproline, and gene expression was quantified by way of quantitative polymerase chain reaction. Liver angiogenesis, macrophage infiltration, and hypoxia were assessed by way of CD31, CD68 and hypoxia-inducible factor-1alpha immunostaining. Cilengitide decreased overall vessel formation. This was significant in portal areas of BDL and septal areas of TAA fibrotic rats and was associated with a significant increase of liver collagen by 31% (BDL) and 27% (TAA), and up-regulation of profibrogenic genes and matrix metalloproteinase-13. Treatment increased gamma glutamyl transpeptidase in both models, while other serum markers remained unchanged. alphavbeta3 inhibition resulted in mild liver hypoxia, as evidenced by up-regulation of hypoxia-inducible genes. Liver infiltration by macrophages/Kupffer cells was not affected, although increases in tumor necrosis factor alpha, interleukin-18, and cyclooxygenase-2 messenger RNA indicated modest macrophage activation. CONCLUSION: Specific inhibition of integrin alphavbeta3 (alphavbeta5) in vivo decreased angiogenesis but worsened biliary (BDL) and septal (TAA) fibrosis, despite its antifibrogenic effect on HSCs in vitro. Angiogenesis inhibitors should be used with caution in patients with hepatic fibrosis.
Authors: Sylvie Maubant; Dominique Saint-Dizier; Morgane Boutillon; Francoise Perron-Sierra; Patrick J Casara; John A Hickman; Gordon C Tucker; Ellen Van Obberghen-Schilling Journal: Blood Date: 2006-07-11 Impact factor: 22.113
Authors: Oliver Baum; Ruslan Hlushchuk; Andrea Forster; Richard Greiner; Philipp Clézardin; Yingshe Zhao; Valentin Djonov; Günther Gruber Journal: Int J Oncol Date: 2007-02 Impact factor: 5.650
Authors: Jie Ren; Joan Avery; Haibo Zhao; Jochen G Schneider; F Patrick Ross; Anthony J Muslin Journal: J Mol Cell Cardiol Date: 2006-12-20 Impact factor: 5.000
Authors: Duk-Hee Kang; Jeremy Hughes; Marilda Mazzali; George F Schreiner; Richard J Johnson Journal: J Am Soc Nephrol Date: 2001-07 Impact factor: 10.121
Authors: Duk-Hee Kang; Alison H Joly; Se-Woong Oh; Christian Hugo; Dontscho Kerjaschki; Katherine L Gordon; Marilda Mazzali; J Ashley Jefferson; Jeremy Hughes; Kirsten M Madsen; George F Schreiner; Richard J Johnson Journal: J Am Soc Nephrol Date: 2001-07 Impact factor: 10.121
Authors: M P Bendeck; C Irvin; M Reidy; L Smith; D Mulholland; M Horton; C M Giachelli Journal: Arterioscler Thromb Vasc Biol Date: 2000-06 Impact factor: 8.311
Authors: Jonathan A Fallowfield; Masashi Mizuno; Timothy J Kendall; Christothea M Constandinou; R Christopher Benyon; Jeremy S Duffield; John P Iredale Journal: J Immunol Date: 2007-04-15 Impact factor: 5.422
Authors: Vincent Sarrazy; Anne Koehler; Melissa L Chow; Elena Zimina; Chen X Li; Hideyuki Kato; Christopher A Caldarone; Boris Hinz Journal: Cardiovasc Res Date: 2014-03-17 Impact factor: 10.787
Authors: Dominique Thabut; Chittaranjan Routray; Gwen Lomberk; Uday Shergill; Kevin Glaser; Robert Huebert; Leena Patel; Tetyana Masyuk; Boris Blechacz; Andrew Vercnocke; Erik Ritman; Richard Ehman; Raul Urrutia; Vijay Shah Journal: Hepatology Date: 2011-06-26 Impact factor: 17.425